BDUUF vs MSFT: Which Stock is Better?
Side-by-side comparison of Bangkok Dusit Medical Services Public Company Limited and Microsoft Corp in 2026
BDUUF
Bangkok Dusit Medical Services Public Company Limited
$0.65
MSFT
Microsoft Corp
$417.51
Key Metrics Comparison
| Metric | BDUUF | MSFT | Winner |
|---|---|---|---|
| Market Cap | $10.33B | N/A | BDUUF |
| P/E Ratio | 21.67 | 26.46 | BDUUF |
| EPS (TTM) | $0.03 | $15.98 | MSFT |
| Revenue Growth | 0.0% | 0.2% | MSFT |
| Gross Margin | 37.1% | 68.6% | MSFT |
Analyze BDUUF
Full quant analysis
Analyze MSFT
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is BDUUF or MSFT a better investment?
Comparing BDUUF and MSFT: Bangkok Dusit Medical Services Public Company Limited has a market cap of $10.33B while Microsoft Corp has N/A. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between BDUUF and MSFT?
BDUUF (Bangkok Dusit Medical Services Public Company Limited) and MSFT (Microsoft Corp) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: BDUUF or MSFT?
Based on P/E ratios, BDUUF trades at a lower multiple (21.7x vs 26.5x).
Which is growing faster: BDUUF or MSFT?
MSFT has higher revenue growth at 0.2% vs 0.0% for BDUUF.
Which company is more profitable: BDUUF or MSFT?
Microsoft Corp (MSFT) has higher gross margins at 68.6% compared to 37.1% for BDUUF.
Which is the larger company: BDUUF or MSFT?
Bangkok Dusit Medical Services Public Company Limited (BDUUF) is larger with a market cap of $10.33B compared to N/A for MSFT.
Should I buy BDUUF or MSFT in 2026?
Both BDUUF and MSFT have investment merit. BDUUF trades at $0.65 while MSFT trades at $417.51. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between BDUUF and MSFT stock?
Key differences: Market Cap ($10.33B vs N/A), P/E Ratio (21.7x vs 26.5x), Revenue Growth (0.0% vs 0.2%), Gross Margin (37.1% vs 68.6%).